Redeye’s analyst provides an update following the NextCell's year-end report, which also marks the transition to a standard calendar fiscal year. With an expanding body of long-term data in the adult population and strategic progress toward opportunities in Asia, NextCell enters 2026 positioned for material newsflow. Notably, the Phase II ProTrans-Young readout expected in Q3 2026 represents a catalyst that could meaningfully influence both valuation and partnership discussions.
LÄS MER
